Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/88734
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Applied Biology and Chemical Technology | - |
dc.creator | Watson, AL | - |
dc.creator | Anderson, LK | - |
dc.creator | Greeley, AD | - |
dc.creator | Keng, VW | - |
dc.creator | Rahrmann, EP | - |
dc.creator | Halfond, AL | - |
dc.creator | Powell, NM | - |
dc.creator | Collins, MH | - |
dc.creator | Rizvi, T | - |
dc.creator | Moertel, CL | - |
dc.creator | Ratner, N | - |
dc.creator | Largaespada, DA | - |
dc.date.accessioned | 2020-12-22T01:07:26Z | - |
dc.date.available | 2020-12-22T01:07:26Z | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | http://hdl.handle.net/10397/88734 | - |
dc.language.iso | en | en_US |
dc.publisher | Impact Journals LLC | en_US |
dc.rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | en_US |
dc.rights | The following publication Watson A. L., Keller B. J., Williams K. A., Damle N. N., Finnerty S. J., Anderson L. K., Greeley A. D., Keng V. W., Rahrmann E. P., Halfond A. L., Powell N. M., Collins M. H., Rizvi T., et al Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget. 2014; 5: 1502-1514 is available at https://dx.doi.org/10.18632/oncotarget.1609 | en_US |
dc.subject | Malignant peripheral nerve sheath tumors | en_US |
dc.subject | Plexiform neurofibromas | en_US |
dc.subject | Schwann cells | en_US |
dc.subject | Neurofibromatosis type 1 syndrome | en_US |
dc.subject | Neurofibromin 1 | en_US |
dc.subject | PI3K/AKT/mTOR signaling | en_US |
dc.subject | MAPK signaling | en_US |
dc.subject | Targeted therapies | en_US |
dc.subject | Genetically engineered mouse models | en_US |
dc.subject | Combination therapy | en_US |
dc.title | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.spage | 1502 | - |
dc.identifier.epage | 1514 | - |
dc.identifier.volume | 5 | - |
dc.identifier.issue | 6 | - |
dc.identifier.doi | 10.18632/oncotarget.1609 | - |
dcterms.abstract | Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that occur spontaneously, or from benign plexiform neurofibromas, in the context of the genetic disorder Neurofibromatosis Type 1 (NF1). The current standard treatment includes surgical resection, high-dose chemotherapy, and/or radiation. To date, most targeted therapies have failed to demonstrate effectiveness against plexiform neurofibromas and MPNSTs. Recently, several studies suggested that the mTOR and MAPK pathways are involved in the formation and progression of MPNSTs. Everolimus (RAD001) inhibits the mTOR and is currently FDA approved for several types of solid tumors. PD-0325901 (PD-901) inhibits MEK, a component of the MAPK pathway, and is currently in clinical trials. Here, we show in vitro than MPNST cell lines are more sensitive to inhibition of cellular growth by Everolimus and PD-901 than immortalized human Schwann cells. In combination, these drugs synergistically inhibit cell growth and induce apoptosis. In two genetically engineered mouse models of MPNST formation, modeling both sporadic and NF1-associated MPNSTs, Everolimus, or PD-901 treatment alone each transiently reduced tumor burden and size, and extended lifespan. However, prolonged treatment of each single agent resulted in the development of resistance and reactivation of target pathways. Combination therapy using Everolimus and PD-901 had synergistic effects on reducing tumor burden and size, and increased lifespan. Combination therapy allowed persistent and prolonged reduction in signaling through both pathways. These data suggest that co-targeting mTOR and MEK may be effective in patients with sporadic or NF1-associated MPNSTs. | - |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Oncotarget, Mar. 2014, , v. 5, no. 6, p. 1502-1514 | - |
dcterms.isPartOf | Oncotarget | - |
dcterms.issued | 2014-03 | - |
dc.identifier.isi | WOS:000336964000009 | - |
dc.identifier.pmid | 24681606 | - |
dc.description.validate | 202012 bcrc | - |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_Scopus/WOS | en_US |
dc.description.pubStatus | Published | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Watson_Co-Targeting_Mapk_Pi3K.pdf | 2.99 MB | Adobe PDF | View/Open |
Page views
60
Last Week
0
0
Last month
Citations as of May 12, 2024
Downloads
20
Citations as of May 12, 2024
SCOPUSTM
Citations
65
Citations as of May 16, 2024
WEB OF SCIENCETM
Citations
58
Last Week
1
1
Last month
Citations as of May 16, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.